Search
Search Results
-
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs) specific for CD19 or B cell maturation antigen (BCMA) are...
-
Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor
mTOR, as a serine/threonine kinase, is a widely pursued anticancer target. Multiple clinical trials of mTOR kinase inhibitors are ongoing, but their...
-
-
Evolution of predictive risk factor analysis for chemotherapy-related toxicity
The causes of variation in toxicity to the same treatment regimen among seemingly similar patients remain largely unknown. There was tremendous...
-
Sub-chronic oral toxicity screening of quercetin in mice
BackgroundQuercetin is an organic flavonoid present in several fruits and vegetables. The anti-inflammatory, antiviral, antioxidant,...
-
CAR-T Cell Therapy: the Efficacy and Toxicity Balance
Purpose of ReviewChimeric antigen receptor (CAR) T cell therapy is an immunotherapy that has resulted in tremendous progress in the treatment of...
-
Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity
Taxanes are a widely used class of anticancer agents that play a vital role in the treatment of a variety of cancers. However, toxicity remains a...
-
A prediction model for severe hematological toxicity of BTK inhibitors
Bruton’s tyrosine kinase inhibitor (BTKi) has revolutionized the treatment of B-cell lymphomas. However, BTKi-related hematological toxicity hinders...
-
A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials
BackgroundThe past few decades have seen remarkable developments in dose-finding designs for phase I cancer clinical trials. While many of these...
-
MB2033, an anti-PD-L1 × IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicity
Interleukin-2 (IL-2), a cytokine with pleiotropic immune effects, was the first approved cancer immunotherapy agent. However, IL-2 is associated with...
-
Financial toxicity among cancer survivors: a conceptual model based on a feedback perspective
PurposeExperiencing financial toxicity following a cancer diagnosis is a circular and complex process. We investigate the circular causal mechanisms...
-
Self-assembled peptide-dye nanostructures for in vivo tumor imaging and photodynamic toxicity
We report noncovalent assemblies of iRGD peptides and methylene blue dyes via electrostatic and hydrophobic stacking. These resulting nanomaterials...
-
Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes
BackgroundThe rates of local failure after curative radiotherapy for prostate cancer (PC) remain high despite more accurate locoregional treatments...
-
Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes
PurposeTo report the outcomes of a large series of intracranial meningiomas (IMs) submitted to proton therapy (PT) with curative intent.
...
-
Availability and accessibility of services to address financial toxicity described by Australian lung cancer patients and healthcare professionals
PurposeAlthough the financial burden and impact of a cancer diagnosis has been widely described in international literature, less understood is the...
-
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and care of patients with cancer owing to unique features, including the...
-
-
Efficacy and toxicity of infradiaphragmal radiotherapy fields in lymphoma patients: a single-centre experience
PurposeData on efficacy and toxicity of infradiaphragmal radiotherapy fields in lymphoma patients are scarce. We therefore performed this...
-
Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team
BackgroundDespite the efficacy of immune checkpoint inhibitors (ICIs), adverse events including hepatotoxicity limit their ongoing use. We...
-
Predictors of toxicity after curative reirradiation with intensity modulated radiotherapy or proton therapy for recurrent head and neck carcinoma: new dose constraints for pharyngeal constrictors muscles and oral cavity
BackgroundOur study aims to identify predictive factors of moderate to severe (grade ≥ 2) late toxicity after reirradiation (reRT) of recurrent head...
